Cell And Gene Therapy Videos

  1. A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol 1/23/2025

    Learn about a novel LCMS assay for 4β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

  2. Beyond CRISPR: Next-Gen Gene Editing With TARGATT, Mad7, Base Editing 1/17/2025

    Consider several gene editing technologies — TARGATT, Mad7, and Base Editing — and gain insights into their transformative applications in genetic engineering and therapeutic development.

  3. The Future Of Allogeneic Cell Therapy: Hypoimmunogenic Donor Cells 1/17/2025

    Explore how TARGATT® gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

  4. The Crucial Role Of Apheresis In Cellular Therapies 1/8/2025

    Gain valuable insights into the critical role of apheresis in sourcing high-quality cellular material for therapies.

  5. BioPhorum Raw Materials Risk Assessments 12/19/2024

    Torsten Schaderdorf provides an in-depth exploration of current regulations related to Raw Materials Risk Assessment, highlighting the risk criteria and raw material scope outlined in the BioPhorum guidelines.

  6. How Standardized Extractables Data Support E&L Risk Assessment 12/19/2024

    Explore E&L evaluations, USP <665>, supplier-provided extractables data, and collaborative strategies to mitigate risks in Single-Use Systems for biopharmaceutical manufacturing processes.

  7. Pioneers And Visionaries Of Nucleic Acid And Nanoparticle-Based Therapeutics 12/12/2024

    Explore the future of nucleic acid and nanoparticle-based therapeutics, including mRNA, CRISPR, and gene editing, as experts discuss innovative solutions for complex health challenges.

  8. From Platform To Patient: Streamlining Gene Therapy Development 12/5/2024

    Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

  9. Early Preclinical Development: A Successful Transition To cGMP Manufacturing 12/2/2024

    Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

  10. How To Boost AAV Titer With Feed Supplementation In Both HEK293 And Sf-9 Platforms 11/25/2024

    Explore how optimizing post-transfection or post-infection feeding in HEK293 and Sf-9 cells significantly boosts AAV titers, enhancing production efficiency for gene therapy applications.